Important role of translational science in rare disease innovation, discovery, and drug development

Journal of General Internal Medicine

Volumn 29, Issue SUPPL. 3, 2014, Pages

  Pariser, Anne R ^a   Gahl, William A ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

diagnosis; rare disease; registries; translational medical research

Indexed keywords

DRUG DEVELOPMENT; EXPERIMENTAL THERAPY; HUMAN; MEDICAL RESEARCH; RARE DISEASES; TRANSLATIONAL RESEARCH;

BIOMEDICAL RESEARCH; DRUG DISCOVERY; HUMANS; RARE DISEASES; THERAPIES, INVESTIGATIONAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84905908744     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2881-2     Document Type: Article

References (22)

1. Orphan Drug Act, Pub. L. 97-414. 96 Stat. 2049 (1983). Amended in 1984 by Pub. L. 98-551 to add a numeric prevalence threshold to the definition of rare diseases.
2. U.S. Food and Drug Administration (FDA). Search orphan drug designations and approvals. Available at: http://www.accessdata.fda.gov/scripts/opdlisting/ oopd/. Accessed February 5, 2014.
3. Clark TG, Mallard K, Coll F, et al. Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One. 2013;8:e83012. doi:10.1371/journal.pone.0083012.
4. Shaw AT, Kim D, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-94.
5. Craven A, Robson J, Ponte C, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013;17:619-21.
6. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663-72.
7. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-14.
8. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-703.
9. U.S. FDA. Drugs@FDA. Available at: http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm. Accessed March 19, 2014.
10. Engel PA, Bagal S, Broback M, Boice N. Physician and patient perceptions regarding physician training in rare diseases: The need for stronger educational initiatives for physicians. J Rare Dis. 2013;1:1-15.
11. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med. 2013;369:1502-11.
12. Gahl WA. The battlefield of rare diseases: where uncommon insights are common. Sci Transl Med. 2012;4:1-3.
13. Yuan H, Hansen KB, Zhang J, et al. Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy. Nat Commun. 2014;5:3251. doi:10.1038/ncomms4251.
14. Pierson TM, Yuan H, Fuentes Fajardo K, et al. De novo GRIN2A mutation results in early-onset epileptic encephalopathy; Personalized therapy with memantine. Ann Clin Transl Neurol. 2014, in press.
15. Gahl WA, Tifft CJ. The NIH undiagnosed diseases program: lessons learned. JAMA. 2011;305:1904-5.
16. Gahl WA, Markello TC, Toro C, et al. The National Institutes of Health undiagnosed diseases program: insights into rare diseases. Genet Med. 2012;14:51-9.
17. Gahl WA, Boerkoel CF, Boehm M. The NIH undiagnosed diseases program: bonding scientists and clinicians. Dis Model Mechanobiol. 2012;5:3-5.
18. NIH, National Center for Advancing Translational Sciences, Office of Rare Diseases Research. Global Rare Disease Patient Registry and Data Repository (GRDR). Available at: https://rarediseases.info.nih.gov/research/pages/43/ global-rare-disease-patient-registry-and-data-repository. Accessed February 5, 2014.
19. Cystic Fibrosis Foundation. Patient Registry Report. Available at: http://www.cff.org/livingwithcf/qualityimprovement/patientregistryreport/ Accessed February 5, 2014.
20. Sasinowski FJ. Quantum of effectiveness evidence in FDA's approval of orphan drugs. Drug Inf J. 2012;46:238-63.
21. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31:1834-41.
22. Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patients populations. Sci Transl Med. 2013;5:1-14.